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Mineralocorticoid (MR) and glucocorticoid receptors (GR) are abundantly expressed in the limbic brain and mediate cortisol
effects on the stress-response and behavioral adaptation. Dysregulation of the stress response impairs adaptation and is a risk
factor for depression, which is twice as abundant in women than in men. Because of the importance of MR for appraisal
processes underlying the initial phase of the stress response we investigated whether speciﬁc MR haplotypes were associated
with personality traits that predict the risk of depression. We discovered a common gene variant (haplotype 2, frequency B0.38)
resulting in enhanced MR activity. Haplotype 2 was associated with heightened dispositional optimism in study 1 and with less
hopelessness and rumination in study 2. Using data from a large genome-wide association study we then established that
haplotype 2 was associated with a lower risk of depression. Interestingly, all effects were restricted to women. We propose that
commonfunctionalMRhaplotypesareimportantdeterminantsofinter-individualvariabilityinresiliencetodepressioninwomen
by differentially mediating cortisol effects on the stress system.
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Introduction
A fundamental question in mental health research is why
some individuals can cope with stress while others can’t and
become vulnerable for depression. Tipping the balance from
resilience to vulnerability occurs upon dysregulation of brain
mineralo- (MR)- and glucocorticoid receptors (GR), which
mediate the action of the adrenal hormone cortisol on the
initiation and termination of the stress response, respec-
tively.
1,2 Chronically elevated cortisol activating GR is a
known risk factor for depression
3 and blockade of excess
cortisol with GR antagonists has been successful in the
treatment of psychotic depression.
4 In addition, abundant
evidence points to MR activation in the limbic brain as a
potential antidepressant strategy.
3,5–9
Previously we identiﬁed two single-nucleotide polymorph-
isms(SNPs)locatedinexon2oftheMR(NR3C2)gene( 2G/
C and I180V; Figure 1a) that inﬂuence MR translation and/or
its capacity to transactivate target genes in cell lines. These
two SNPs caused differential neuroendocrine and sympa-
thetic responses to psychological stressors.
10,11 In addition,
these SNPs were associated with differences in the cortisol
awakening response, depending on an interaction with
selective serotonin reuptake inhibitors or after dexametha-
sone treatment.
12,13 Most of the associations found with the
MR SNPs were sex-dependent. Here, we assessed whether
the functional SNPs in exon 2 are linked to SNPs in the MR
promoter region, which potentially inﬂuence MR transcription
and its dynamic expression. We identiﬁed a common gene
variant (haplotype 2, frequency B0.38) that enhances MR
synthesis. Next, our objective was to examine if the MR
haplotypes protect against depression. We discovered that
MR haplotype 2 enhances resilience to depression, particu-
larly in women and have replicated this ﬁnding in three
independent studies, including data from a genome-wide
association study.
Materials and methods
SNP analysis of the MR promoter region and luciferase
assays. A total of 50 anonymous blood samples were
obtained from the general physician laboratory in Leiden.
DNA was isolated and the MR gene’s coding sequence was
analyzed for the occurrence of SNPs, including the  2G/C
and I180V SNPs, as described by DeRijk et al.
14 In the
present study, a region of almost 4kb (3870 basepairs) of the
50 untranslated region (50 UTR) was ampliﬁed with multiple
PCR reactions followed by sequence analysis. Based on the
literature and with in silico analysis we veriﬁed whether the
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www.nature.com/tpcommon SNPs in this 4kb promoter region were located in
(predicted) transcription factor- (TF) binding sites, glucocor-
ticoid responsive elements, binding of other steroid receptors
(using the TF databases TRANSFAC
15 and JASPAR
16), or
whether they would inﬂuence splicing of the MR transcripts.
17
Haplotypes were reconstructed and for the three haplo-
types with a frequency above 0.03 (designated as haplotype
1, 2 or 3) ﬁreﬂy luciferase reporter plasmids were constructed
using the pGL3-Basic plasmid (Promega, Leiden, The
Netherlands). Two separate bacterial cultures and plasmid
DNA isolates were prepared for each of the three haplotype-
ﬁreﬂy luciferase constructs on two distinct days. Differential
promoter activity between the three haplotypes was tested in
human neuroblastoma cells (BE(2)-M17; Health Protection
Agency Culture Collections, Cat. No. 95011816). Cells were
transfected with 200ng of haplotype-ﬁreﬂy luciferase con-
struct 1, 2 or 3, together with 10ng of a Renilla luciferase
reporterplasmid(pGL4.74(hRluc/TK),Promega). Inseparate
culture wells, 100ng of pGL3-Basic or pGL3-Control vector
(Promega) were transfected, functioning as, respectively,
background measurement or positive control. Each construct
was transfected in six separate wells. After 48h of incubation,
cells were lysed and ﬁreﬂy and Renilla luminescent activity
was assessed. Experiments were performed three times on
separate days for each of the two sets of plasmid DNA
isolates. Relative light units were calculated by dividing the
ﬁreﬂy luminescent signals by the corresponding Renilla
luminescent signals in order to correct for variability in
transfection efﬁciency or cell death (see Supplementary
Methods and Supplementary Table 1 for further details).
Study 1: association with dispositional optimism. The
ﬁrst study group consisted of 450 elderly men and women
who previously participated in the 9.1-year longitudinal
Arnhem Elderly Study
18 (see Supplementary Methods and
Supplementary Table 4 for sample characteristics). Disposi-
tional optimism was assessed using the Dutch Scale of
Subjective Well-being for Older Persons (Groningen
University, The Netherlands).
19 The Dutch Scale of Subjec-
tive Well-being for Older Persons consists of ﬁve sub-
scales including Health, Self-respect, Morale, Contacts and
Optimism. For each subscale an individual could indicate to
what extent it conforms to a particular statement on a
3-point scale (from 0 to 2). An example of one of the seven
statements for optimism is: ‘I still have positive expecta-
tions concerning my future’ (our translation). A mean item
score for the optimism subscale was calculated and
multiplied by 10, resulting in scores ranging from 0 to 20,
with higher scores indicating a higher level of optimism.
Participants provided a blood sample for genotype analysis.
This study was approved by the Medical Ethics Committee of
Wageningen University (Wageningen, The Netherlands). All
participants provided written informed consent.
Figure 1 (a)Schematicoverviewofthehumanmineralocorticoid receptor(MR)genewith itsrespective50 haplotypesandhaplotypefrequencies.Threehaplotypesalong
a stretch of 4kb of the 50 untranslated region were identiﬁed based on the genotypes of 50 anonymous DNA samples and include eight single-nucleotide polymorphisms
(SNPs). The positioning and relation with the -2G/C (rs2070951) and I180V (rs5522, control SNPs in grey) SNPs are indicated, which tag these three most common
haplotypes. The haplotypes are not linked to common SNPs more 30 in the MR gene sequence, as a recombination hotspot exists in intron 2 (asterisk). (b) Mean activity
(±s.e.m., N¼6) of the human MR promoter region associated with haplotype 1, 2 or 3. The ﬁgure shows representative results (of three independent experiments with two
distinctsetsofplasmidisolates)onthecomparisonofpromoteractivitiesassociatedwithhaplotype1–3relativetotheactivityofthepGL3-Basicplasmid,whichactivitywasset
to 1 (data not shown). Activities differed signiﬁcantly between the three MR plasmids (F(2,15)¼27.98; Po0.001). Data are ﬁreﬂy luminescent signals divided by the Renilla
luminescentsignals,herebycontrolling for celldeath andvariabilityin transfectionefﬁciency.*Po0.05;**Po0.01;***Po0.001.Abbreviations: P1,promoter1; P2, promoter
2; UTR, untranslated region.
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Translational PsychiatryStudy 2: association with cognitive reactivity to sad
mood. As a follow-up on the ﬁrst study, this second study
was performed to test the association between the MR
haplotypes and hopelessness, which is by deﬁnition inversely
related to optimism. The second study group consisted of
150 university students (see Supplementary Methods and
Supplementary Table 5 for sample characteristics). Thoughts
of hopelessness during sad mood as well as several other
measures of cognitive reactivity were assessed with the
Leiden Index of Depression Sensitivity-revised.
20 It is a
self-rating questionnaire consisting of 34 items and six
subscales, namely Hopelessness/Suicidality, Acceptance/
Coping, Aggression, Perfectionism/Control, Risk Aversion
and Rumination. An example of one of the ﬁve statements for
Hopelessness/Suicidality is: ‘When I feel down, I more often
feel hopeless about everything’. Participants had to indicate
whether and how their thinking patterns change when they
experience mild dysphoria, by scoring each item on a 5-point
Likert-scale ranging from 0 ‘not at all’ to 4 ‘very strongly’.
Scores for Hopelessness/Suicidality range from 0 to 20.
In addition, scores were assessed for neuroticism (Neuroti-
cism-Extraversion-Openness Five-Factor Inventory
21), cur-
rent symptoms of anxiety and depression (Hospital Anxiety
and Depression Scale
22) and the presence of current and
past depression (Major Depression Questionnaire
23). Partici-
pants provided a saliva sample for genotype analysis. This
study was approved by the Ethics Committee of the Leiden
University Medical Center (Leiden, The Netherlands). All
participants gave written informed consent.
Study 3: association with the risk of depression. To test
association of the MR haplotypes with major depressive
disorder (MDD) in a larger study sample, data were used
from a genome-wide association study, the GAIN-MDD
study.
24 MDD cases (n¼1730) were mainly from the
Netherlands Study of Depression and Anxiety (NESDA;
http://www.nesda.nl).
25 The patients included here had a
lifetime diagnosis of MDD as diagnosed with the DSM-IV
Composite International Diagnostic Interview version 2.1.
26
The control subjects (n¼1793; mean age±s.d.¼45.1±
14.1), having no report of MDD, were mainly from the
Netherlands Twin Registry (http://www.tweelingenregister.
org).
27 Participants provided a blood sample for genotype
analysis. The NESDA and The Netherlands Twin Registry
studies were approved by the Central Ethics Committee
on Research Involving Human Subjects of the VU Univer-
sity Medical Center, Amsterdam, The Netherlands. All
subjects provided written informed consent (see Supple-
mentary Methods and Supplementary Table 6 for sample
characteristics).
DNA isolation and genotyping. DNA was isolated from
the blood (ﬁrst and third study group) or saliva (second
study group) samples and genotypes were assessed for
the functional MR  2G/C (rs2070951_GC) and I180V
(rs5522_AG) SNPs, which tag the three most common
haplotypes localized in exon 2 and extending into the
promoter region (Figure 1a; see Supplementary Methods
and Sullivan et al.
24 for further details).
Statistical analysis. SNP allele frequencies were tested for
Hardy–Weinberg Equilibrium using HaploView (version 4.1.
for Mac OS X; available online, http://www.broadinstitute.org/
mpg/haploview).
28 In addition, HaploView was used to assess
inter-marker linkage disequilibrium (LD) scores (expressed as
D’ and r
2) between the MR SNPs and to reconstruct haplo-
types. Individual haplotypes were reconstructed in SNPHAP
(version 1.3; available online, http://www-gene.cimr.cam.ac.
uk/clayton/software/snphap.txt).
To compare promoter activities between the three con-
structs containing haplotype 1, 2 or 3, a one-way analysis of
variance was conducted followed by a post hoc Bonferroni
multiple comparison test.
Differences between men and women on the various
demographics and health factors were tested using an
independent-samples t-test, a w
2-test or a Mann–Whitney
U-test, where appropriate. A square-root transformation was
performed for the Hopelessness/Suicidality, Acceptance/
Coping, Aggression, Perfectionism/Control, Hospital Anxiety
and Depression Scale-depression and -total scales and for
age of the student participants of study 2 (when comparing
age between men and women) in order to normalize their
distributions. Figures 2, 3a and b and Supplementary
Tables 4–6 represent untransformed data, while statistical
tests were performed on transformed data where appropriate
(indicated with an asterisk). Supplementary Table 7
represents transformed data and statistical analysis where
appropriate.
For association analysis with the haplotypes, three dummy
variables were created indicating whether a person carried
zero, one or two alleles of haplotype 1, 2 or 3. With linear
regression analysis the mean effect of one haplotype 2- or 3-
allele on a psychological trait was determined relative to the
referencegroup(scoresinhaplotype1carriers).Todetermine
the effect of two haplotype 2- or 3-alleles, the effect calculated
for one allele can be multiplied by 2. Because of possible sex
Figure 2 Results of study 1, showing crude mean scores (±s.e.m.) for
dispositional optimism according to three 50 mineralocorticoid receptor (MR)
haplotypes in women. Dispositional optimism scores increased 1.7 per haplotype 2
allele (on a range of 0 to 20) only in women (explained variance¼7%) and not in
men (Supplementary Table 7). To determine the effect of two haplotype 2- or 3-
alleles,theeffectcalculatedforoneallelecanbemultipliedby2.P-valuesrepresent
adjusted comparison of haplotype 2 to the reference (haplotype 1 carriers) with
linear regression. Note the breaks in the y axis.
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Translational Psychiatrydifferences, statistical interaction between the MR haplotypes
and sex was determined by adding the two appropriate
interaction terms to the model. Next, regression analyses
were repeated in sex strata. In sensitivity analyses in study 2
subjectswithout a Europeanancestry wereexcluded.Instudy
2 associations between the haplotypes with the other Leiden
Index of Depression Sensitivity-revised subscales, neuro-
ticism and current symptoms of anxiety and depression
was also tested. Logistic regression was used to test
association with self-reported diagnosis of depression. In
thethirdassociationstudy,logisticregressionwasusedtotest
association with MDD. As sex-dependent associations are
potentially due to differences in circulating sex steroids, the
group of women of the GAIN-MDD study was additionally
divided in women older and younger than the mean age for
menopause (B51 years). In all three studies, analysis was
repeated while adjusting for potential confounding effects of
sex (in the total group) and age.
A two-sided P-value o0.05 was considered statistically
signiﬁcant. A Bonferroni correction was applied where
appropriate. All statistical analysis was performed in SPSS,
version 16.0 for Mac OSX (SPSS, Chicago, IL, USA).
Results
MR SNP and haplotype frequencies and predicted
effects on MR transcription. In all, 16 SNPs were
detected along the 4kb MR promoter region. As of October
2011, three SNPs were still not reported elsewhere
(GRCh37:4:149362585:149366454, Ensembl; novel SNP 1,
2 and 3). All allele frequencies of the MR SNPs were in
Hardy–Weinberg Equilibrium (P40.10; see Supplementary
Table 2 and Supplementary Figure 1 for an overview of
individual SNP genotype frequencies and inter-marker r
2
scores). Reconstruction of MR haplotypes resulted in one
haplotype bin that was highly linked to the previously
described MR -2G/C and I180V SNPs. On the basis of
previous research by our lab and the HapMap database
(http://hapmap.ncbi.nlm.nih.gov) we know that these exon 2
SNPs are not linked to the rest of the MR gene sequence
starting in intron 2.
14
Poolingthelow frequencyhaplotypes(freq.o0.03)withthe
high frequency haplotypes (based on the  2G/C and I180V
genotypes) resulted in three haplotypes with frequencies of
0.50, 0.41 and 0.09, which differ in eight MR 50 UTR SNPs
(Figure 1a). These eight MR 50 UTR SNPs were not located at
previously described TF-binding sites. However, in silico
analysis using two different databases consistently predicted
the SNP rs5520 to affect the number of possibilities for Sp1
binding, while the SNP rs3216799 inﬂuences Hepatocyte
Nuclear Factor 1 b binding (see Supplementary Table 3).
Of interest is that one database predicted the SNP 2248038
to affect a glucocorticoid responsive element-consensus
sequence by inﬂuencing binding of NR3C1 (or GR), while
the SNP rs3216799 was predicted to be located 1 nucleo-
tide next to a glucocorticoid responsive element (data not
shown). The SNPs did not alter predicted splicing of the MR
transcripts.
Promoter haplotype 2 results in higher MR
expression. Results of three independent experiments
with two separate sets of plasmid isolates were highly
similar. All three MR promoter regions were active under
non-stimulating conditions, as the constructs resulted in a
signal that was higher compared with the pGL3-Basic
Figure 3 (a, b) Results of study 2, showing crude mean scores (±s.e.m.) for
cognitive reactivity according to three 50 MR haplotypes in women. Hopelessness
(a) scores decreased 1.1-fold per haplotype 2 allele (on a range of 0 to 20), only in
women (explained variance¼4%) but not in men (Supplementary Table 7). In
addition, rumination (b) scores were lower only in the female haplotype 2 carriers,
with a 2.1-fold reduction per haplotype 2 allele (on a range of 0 to 24; explained
variance¼11%). To determine the effect of two haplotype 2- or 3-alleles, the effect
calculated for one allele can be multiplied by 2. P-values represent adjusted
comparison of haplotype 2 to the reference (haplotype 1 carriers) with linear
regression. Note the breaks in the y axis. * Statistical test based on transformed
data. (c) Percentage of female students reporting a diagnosis for depression
according to the number of haplotypes 2 (odds ratio¼0.40; 95% conﬁdence
interval¼0.16–0.95; P¼0.04). For statistical test results see also Supplementary
Table 8a.
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Translational Psychiatryplasmid (Figure 1b). Activities between the three plasmids
differed signiﬁcantly (F(2,15)¼27.98; Po0.001). Haplotype
2 resulted in a 1.4 times higher promoter activity compared
with haplotype 1 (Po0.01) and a 2.2 times higher promoter
activity compared with haplotype 3 (Po0.001).
Haplotype frequencies in the three association study
groups. Allele frequencies of the MR SNPs were in Hardy–
Weinberg Equilibrium (P40.10). Genotype and haplotype
frequencies (see Supplementary Tables 4–6) and inter-
marker correlations between the MR -2G/C (rs2070951)
and I180V (rs5522) SNPs (D’¼1.0; r
2¼0.15) were similar as
previously found.
10
Study 1: MR haplotype 2 associates with higher
dispositional optimism, speciﬁcally in women. MR
haplotype 2 (freq. 0.36) was associated with higher disposi-
tional optimism when compared with the reference group
(haplotype 1 carriers; P¼0.01; Supplementary Table 7).
Importantly, a MR haplotype 2-by-sex interaction effect
was found (P¼0.01). Data stratiﬁcation for sex revealed
that only in women haplotype 2 was related to higher levels of
dispositional optimism (Figure 2) with an explained variance
was 7% (R
2change¼0.07), while no signiﬁcant effect was
found in men.
Study 2: MR haplotype 2 associates with fewer thoughts
of hopelessness, speciﬁcally in women. Haplotype 2 was
signiﬁcantly associated with fewer thoughts of hopelessness,
again only among female students (Figure 3a), with an
explained variance of 4% (R
2change¼0.04).
Interestingly, additional analysis of the other ﬁve Leiden
Index of Depression Sensitivity-revised subscales showed
that in women haplotype 2 was also signiﬁcantly associated
with lower scores for aggression (P¼0.007), risk aversion
(P¼0.05) and importantly, rumination (Figure 3b; Po0.001;
after a Bonferroni correction for in total twelve tests for the
association with six subscales in both sexes, with a
signiﬁcance threshold of Po0.004, this is still signiﬁcant).
Moreover, in women MR haplotype 2 associated with lower
neuroticism scores (P¼0.04), a lower odds ratio for self-
reported diagnosis of depression according to a dominant
model (0.40; 95% conﬁdence interval¼0.16–0.95; P¼0.04;
Figure 3c and Supplementary Table 8a; similar results were
foundwitha linearmodel but showedsmaller effect sizes)and
a trend was found for less symptoms of depression (P¼0.07,
see Supplementary Results and Supplementary Table 7).
Results strengthened after excluding subjects (22 women,
4 men) who indicated that one or both of their parents did not
have a European ancestry or who did not respond to this
question.
Study 3: MR haplotype 2 associates with a lower risk of
major depressive disorder, speciﬁcally in women. The
data of study group 3 were analyzed in two steps and
revealed that MR haplotype 2 was associated with a lower
risk of depression again only in women and not in men, but
strongly depending on whether the women were aged above
or below the mean age for menopause (B51 years). In the
ﬁrst step a trend was found for an association between MR
haplotype 2 and a lower odds ratio for MDD in the total group
of women (0.85; 95% conﬁdence interval¼0.72–1.02;
P¼0.08) and not in men (P¼0.72), again according to a
dominant model (Figure 4a and Supplementary Table 8b;
similar results were found with a linear model but showed
smaller effect sizes). Importantly, data stratiﬁcation for
the mean age for menopause in the second analysis step
(MR haplotype 2-by-age split at 51 years interaction
P¼0.004) showed that MR haplotype 2 associated with a
Figure 4 Results of study 3, showing the percentage of women diagnosed with
major depressive disorder (MDD) according to the number of haplotypes 2. Results
are presented for the total group of women (a) (odds ratio¼0.85; 95% conﬁdence
interval¼0.72–1.02; P¼0.08), for the women aged p51 years (odds
ratio¼0.75; 95% conﬁdence interval¼0.60–0.93; P¼0.009) (b), or for the
women aged p41 years (odds ratio¼0.66; 95% conﬁdence interval¼0.52–0.86;
P¼0.002) (c). MDD cases were mainly from the Netherlands Study of Depression
and Anxiety cohort (NESDA),
25 healthy controls were mainly from the Netherlands
Twin Registry (NTR).
27 For statistical test results see Supplementary Table 8b.
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age p51 years (0.75; 95% conﬁdence interval¼0.60–0.93;
P¼0.009; after a Bonferroni correction for in total four tests
for association analysis within both sexes and within the two
age groups, with a signiﬁcance threshold of Po0.0125, this
is still signiﬁcant; Figure 4b). The association particularly
existed in the women with an age p41 years (0.66; 95%
conﬁdence interval¼0.52–0.86; P¼0.002; Figure 4c; MR
haplotype 2-by-age split at 41 years interaction P¼0.008).
Discussion
The ﬁndings show that in three distinct groups of subjects the
common and functional MR haplotype 2 was associated with
optimism and a lower risk of depression in women. Haplotype
2, consisting of the known  2G/C and I180V SNPs
11,13,29 and
several promoter SNPs results in higher MR activity at the
transcriptional, translational and transactivational level.
10
Previously, MR expression was found to be decreased in the
limbic brain of depressed subjects.
6 Moreover, the MR
is induced by antidepressant treatment, with MR induction
potentiallycontributingtoantidepressanttreatmentsuccess.
8,9
MR agonists and antagonists either enhance or suppress
antidepressant efﬁcacy, respectively,
5,7 whereas modulatory
effects of SNPs in the MR gene on the cortisol response to
stress have been reported.
10,11 This implicates cortisol
action via the MR as an important determinant of the inter-
individual differences in stress responsiveness and vulner-
ability for depression. Indeed, in a previous study an
association was found between the MR I180V SNP and
geriatric depression.
29
Possibly the MR promoter SNPs are to a large extent
responsiblefortheinter-individualdifferences.MRexpression
is highly dynamic, showing changes during development,
agingandafterphysicalorpsychologicalstress.
30–35Context-
dependent changes in MR expression can be established by
distinct50 MR mRNA transcripts(MRa andMRb),eachhaving
its own promoter containing regulatory elements and showing
differential expression depending on tissue, time and avail-
ability of steroids and stress.
6,30,36–38 SNPs may result in
differential expression of MRa vs MRb by affecting TF binding
or splicing. Two of the eight common 50 UTR SNPs were
consistently predicted to inﬂuence TF binding while a third
SNP was predicted to affect a glucocorticoid responsive
element-consensus sequence (although not consistent).
None of the SNPs was predicted to affect potential binding
sites for sex steroids. Additional in vitro assays, like electro-
phoretic mobility shift assays, are necessary to identify allele-
speciﬁc TF binding.
Intriguingly,theMRhaplotype2appearstoestablishalower
risk of depression diagnosis only in women below 51 and in
particularbelow41yearsofage.Thissuggeststhatfemalesex
steroids may interact with the MR gene, thereby modulating
resilience.TheMRhaplotypesareknowntoconferdifferences
in MR activity with varying ligand availability, while hypotha-
lamic-pituitary-adrenal (HPA) responses to stress are sex-
speciﬁc.
10,39 Moreover, estrogens and progesterone are
known to modulate MR mRNA and/or protein expression, with
possibleconsequencesforstress-reactivity.
40,41Theseeffects
of sex steroids are superimposed on the remarkable promis-
cuity of the brain MR, which can bind also aldosterone and
progesterone, but is particularly occupied by the much higher
concentrations of circulating cortisol. This is because the
cortisol-inactivating enzyme typical for aldosterone selectivity
of the MR in kidney epithelial cells is absent in brain.
42
However, no signiﬁcant interaction effect was found between
the haplotypes and the use of oral contraceptives (data not
shown). Furthermore, the age difference in the association
between the MR haplotypes and depression diagnosis may
also be because of the impact of genetic factors, which is
known to be larger for early-onset rather than late-onset
depression.
43 Although study group 1 and particularly
study group 2 were small, with a rather low power to detect
haplotype-related differences, the three independent studies,
including the larger genome-wide association study dataset,
all pointed to similar and signiﬁcant associations.
In the limbic brain higher MR activity implies an enhanced
reaction to novel information, allowing the individual to better
appraise and perceive a new experience as either stressful or
not. Individuals at risk of depression are thought to cope less
efﬁciently with challenges,
44 a phenomenon clearly linked to
cortisol resistance in the brain to which haplotypes 1 and 3
with reduced activity of the MR may contribute. Also, hope-
lessnessandruminationassociatedwiththesehaplotypesare
risk factors for depression; rumination is a strong predictor of
depressive episodes (correlation¼0.42 for previous Beck
Depression Inventory (BDI) depression, 0.55 for current BDI
depression), whereas hopelessness is not only a predictor
of depressive episodes (correlation¼0.57 for previous BDI
depression, 0.40 for current BDI depression), it is also
related to suicidal ideation during and between depressive
episodes.
45–47 In contrast, the dispositional optimism asso-
ciated with haplotype 2 is a rather stable trait that relates
to successful coping with stressful experiences and pre-
dicts a lower risk of depression (Spearman’s correlation
coefﬁcient¼ 0.50 to  0.63 for depressive symptoms among
elderly during 15 years of follow-up).
48,49
Our data strengthen the hypothesis that disturbed cortisol
effects through impaired central MR signaling underlie in part
the pathophysiology of depression.
1,3 The MR mediates
cortisol-enhanced metaplasticity in the limbic brain involving
the recently discovered membrane variants
50 and the cortisol
effects on appraisal, cognitive and behavioral ﬂexibility and
emotions.
29,51–54 As the hormone cortisol drives gene-
environment interaction, for better, but also for worse, the
data raise the possibility that the cortisol-MR complex
functionssimilarlyastherecentlydesignated‘plasticitygenes’
(like the serotonin transporter gene with its well-known
5-HTTLPR polymorphism), with the reactive alleles rendering
an individual more susceptible to adverse conditions, but also
providing a beneﬁt under supportive conditions.
55
Here, we show that men’s susceptibility to depression does
not seem to be modulated by MR gene variability, while
women’s susceptibility depends on whether they carry MR
haplotype 1 or 3 vs haplotype 2. That the MR haplotype 2
enhances psychological resilience particularly in women is
fascinating considering the twice higher prevalence of
depression in women.
56 The ﬁnding provides a new lead
towards a better understanding of the pathogenesis of this
devastating affective disorder.
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